OPTN - Dana dhuwit perusahaan Optinose

OptiNose, Inc. (OPTN) is scaling the commercial reach of its nasal therapies by expanding the application of drugs for chronic sinusitis in the US. This chart on the GURU.Markets platform illustrates the cash on hand volume, where 0.07 captures the current value of the indicator. The company's revenues are based on the sale of proprietary drug delivery systems for the deep nasal cavities. Efficient component logistics and the diversification of plastic suppliers ensure high distribution margins.
Rincian metrik keuangan lan pasar OptiNose (OPTN)

For OptiNose, Inc., which is competing for the nasal spray segment, the current cash balance serves as a key indicator of viability. This metric aggregates the total of the most liquid assets available for immediate deployment. It measures the business's ability to sustain operations without external borrowing. Amid aggressive marketing against generics, this reserve offsets declining margins. A reduction in funds signals a risk of capital depletion.